Latest Cell Therapy News

Chimeric Therapeutics reports encouraging Phase 1B data from its ADVENT-AML trial, showing safety and multiple complete responses in high-risk AML patients treated with CORE-NK combined with standard therapies.

Chimeric Therapeutics reports encouraging early clinical trial outcomes for its CHM CDH17 CAR-T therapy, showing disease control and tumour shrinkage at higher dose levels with a strong safety profile.

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.

INOVIQ Limited has demonstrated that its CAR-NK-exosome therapy kills over 90% of triple-negative breast cancer cells within 10 hours in laboratory tests, validating its potential as a next-generation cancer treatment.

Mesoblast has entered agreements to issue up to US$50 million in convertible notes, aiming to strengthen its capital base and support pipeline growth, pending shareholder approval.

Osteopore Limited has established OsteoRx, a new special purpose vehicle, with an initial AUD 0.5 million investment to accelerate breakthroughs in cellular regenerative medicine. This strategic move integrates a controlling stake in US-based RxCell Inc, expanding Osteopore’s footprint in the fast-growing stem cell market.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Prescient Therapeutics has completed a $3 million share placement, bolstering its clinical development programs for innovative cancer treatments including PTX-100 and novel cell therapies.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

Mesoblast reports a strong FY2025 financial performance driven by the commercial launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. The company is advancing multiple clinical programs targeting inflammatory diseases, heart failure, and chronic low back pain.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.